1726
|
Ogasawara K. [Is it possible to treat diseases by manipulation of lymphocytes?]. RINSHO BYORI. THE JAPANESE JOURNAL OF CLINICAL PATHOLOGY 2001; 49:1225-32. [PMID: 11797392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Two signals are required for activation of T lymphocytes. Formation of tri-molecular complex among T cell antigen receptor(TCR), major histocompatibility complex(MHC) molecule, and antigen peptide produces signal 1 via TCR. Thus, signal 1 is antigen-dependent. However, signal 2 is elicited by interaction between CD28 and its ligands(CD80 and CD86) and is antigen-independent. Interestingly, cell surface expression of CD80 and CD86 on antigen-presenting cell(APC) is regulated by stimulus via CD40. In this review, it is shown that enhancement of signal 2 by agonistic anti-CD40 antibody increases immune responses, resulting in reinforcement of vaccine efficacy against influenza viruses and murine tumors, if antigen-dependent signal 1 is properly provided. In contrast, inhibition of signal 2 by anti-CD40 ligand(CD154) with pathogenic peptide K2 for EAU(experimental autoimmune uveoretinitis) tolerates T lymphocytes specific for K2, resulting in amelioration of EAU. Accordingly, herein, the possibility of application to humans for immunomanipulation with a controlled stimulus via CD40 is discussed.
Collapse
|
1727
|
|
1728
|
Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology 2001; 104:367-76. [PMID: 11899421 PMCID: PMC1783326 DOI: 10.1046/j.1365-2567.2001.01324.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
1729
|
Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. ALTERNATIVE MEDICINE REVIEW : A JOURNAL OF CLINICAL THERAPEUTIC 2001; 6:540-66. [PMID: 11804546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Multiple sclerosis (MS) is aptly named for the many scars it produces in the brain and spinal cord. A sometimes fatal, often debilitating disease, MS features autoimmune inflammatory attack against the myelin insulation of neurons. Thymus derived (T) cells sensitized against myelin self-antigens secrete tumor necrosis factor, cytokines, prostaglandins, and other inflammatory mediators that strip away the myelin and sometimes destroy the axons. Familial and twin inheritance studies indicate MS is mildly heritable. No single MS locus has been identified, but an HLA haplotype has been implicated. Unique geographic distribution of the disease is best attributed to some combination of vitamin D abnormality and dietary patterns. No pharmaceutical or other therapies exist that confer prolonged remission on MS, and obvious interrelationships between toxic, infectious, and dietary factors make a persuasive case for integrative management. The time-proven MS diet meticulously keeps saturated fats low, includes three fish meals per week, and eliminates allergenic foods. Dietary supplementation for MS minimally requires potent vitamin supplementation, along with the thiol antioxidants, the anti-inflammatory omega-3 fatty acids, and adaptogenic phytonutrients. Gut malabsorption and dysbiosis can be corrected using digestive enzymes and probiotics. Long-term hyperbaric oxygen therapy can slow or remit the disease. Transdermal histamine offers promise, and adenosine monophosphate may sometimes benefit. Chronic viruses and other infectious load must be aggressively treated and exercise should maintain muscle tone and balance. Early intervention with integrative modalities has the potential to make MS a truly manageable disease.
Collapse
|
1730
|
|
1731
|
Rauova L, Rovensky J, Shoenfeld Y. Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. SPRINGER SEMINARS IN IMMUNOPATHOLOGY 2001; 23:447-57. [PMID: 11826620 DOI: 10.1007/s281-001-8170-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
1732
|
Boggio LN, Green D. Acquired hemophilia. REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY 2001; 5:389-404; quiz following 431. [PMID: 11844135 DOI: 10.1046/j.1468-0734.2001.00049.x] [Citation(s) in RCA: 122] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Acquired hemophilia is a serious coagulopathy usually affecting the elderly, persons with autoimmune disorders and, infrequently, women in the immediate postpartum period. It is due to autoantibodies directed against specific domains of the factor VIII molecule, leading to inhibition of factor VIII binding to von Willebrand factor, to activated factor IX or to negatively charged phospholipids. This results in bleeding into the skin, muscles, gastrointestinal and genitourinary tracts, and other sites. Mixing patient plasma with normal plasma prolongs the activated partial thromboplastin time of the normal plasma and the Bethesda assay provides a quantitative estimate of the strength of the inhibitor. The selection of therapeutic concentrates for the management of acute bleeding is related to the titer of the inhibitor; if less than 5 Bethesda Units, human factor VIII may be effective, but higher titer inhibitors usually respond only to porcine factor VIII, recombinant factor VIIa or activated prothrombin complex concentrates. Corticosteroid treatment leads to disappearance of the autoantibody in 50% of patients; cyclophosphamide and cyclosporine are effective in many who do not respond to steroids. Occasionally, high dose intravenous immunoglobulin or immunosorbent columns transiently decrease inhibitor titers and enable control of bleeding. Other autoantibodies have been described against factors V, VII, XI and, rarely, factor XIII and prothrombin. New approaches in the management of autoimmune disease and, especially, methods to establish tolerance are in development.
Collapse
|
1733
|
Bénoliel P. [Treatment of sino-nasal polyposis by Candida albicans immunotherapy: apropos of 4 cases]. ALLERGIE ET IMMUNOLOGIE 2001; 33:388-94. [PMID: 11802479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
UNLABELLED The NSP is an inflammatory chronic disease of the mucous of nose and sinuses. None etiological treatment is known up to now. The aim of this study is to consider a model of autoallergy as etiology for NSP proven by specific immunotherapy (STI) to Candida albicans (CA). METHODS Four NSP treated by SIT to Candida albicans are reported. The patients are treated either by subcutaneous injections or sublingual drops. The frequency is one injection per week or a few drops per day (absorbed extract on calcium phosphate or aqueous Stallergenes). RESULTS The cumulated doses varies from 465 Index of Concentration (IC) to 117500 IC on a period of 3 to 4 years. The results are evaluated according the rhino-sinusal semeiology, the intensity of symptoms, and the stage of polyposis. The SIT is also active on both a late and an immediate components for the symptoms, and the cutaneous tests. The results are significant 60% to 80% of improvement. The viral or bacterial infections reactivate both types of hypersensitivity and they are prevented by SIT. The nasal hyperactivity observed as a more advanced non specific stage of the PNS is also improved by ITS. In two of the clinical cases, the pollenogenic seasonal obstruction is added to the nasal perennial obstruction in a sharp manner. The pollenogenic allergy is also improved after SIT to CA without any other associated SIT. CONCLUSION The model of autoallergy already proven as etiology for atopic dermatitis can serve as a base of exploration of PNS. That is showing the presence of IgE antibody corresponding to intracellular proteinic autoallergens having an analogy to environment allergens. The allergy to Candida albicans can thus be considered as an etiology of the PNS.
Collapse
MESH Headings
- Adult
- Allergens/administration & dosage
- Allergens/immunology
- Allergens/therapeutic use
- Antigens, Fungal/administration & dosage
- Antigens, Fungal/immunology
- Antigens, Fungal/therapeutic use
- Autoantigens/immunology
- Autoimmune Diseases/etiology
- Autoimmune Diseases/immunology
- Autoimmune Diseases/physiopathology
- Autoimmune Diseases/therapy
- Candida albicans/immunology
- Cross Reactions
- Dermatitis, Atopic/immunology
- Desensitization, Immunologic
- Ethmoid Sinusitis/complications
- Ethmoid Sinusitis/therapy
- Humans
- Immunoglobulin E/immunology
- Male
- Middle Aged
- Molecular Mimicry
- Nasal Polyps/etiology
- Nasal Polyps/immunology
- Nasal Polyps/physiopathology
- Nasal Polyps/therapy
- Neoplasm Recurrence, Local
- Paranasal Sinus Neoplasms/etiology
- Paranasal Sinus Neoplasms/immunology
- Paranasal Sinus Neoplasms/physiopathology
- Paranasal Sinus Neoplasms/therapy
- Polyps/etiology
- Polyps/immunology
- Polyps/physiopathology
- Polyps/therapy
- Rhinitis, Allergic, Perennial/complications
- Rhinitis, Allergic, Perennial/physiopathology
- Rhinitis, Allergic, Perennial/therapy
- Rhinitis, Allergic, Seasonal/complications
- Rhinitis, Allergic, Seasonal/therapy
- Skin Tests
Collapse
|
1734
|
Abstract
Growing evidence indicates that structural cells play a crucial role in the chronic inflammation of autoimmunity by their recruitment of chemokine-dependent cells. Members of the two functional classes of chemokines, inflammatory and homeostatic, seem to be involved in lymphocyte recruitment and survival, and in establishing ectopic lymphoid structures in the target organs of autoimmune diseases. Results from animal models suggest that chemokines are reasonable therapeutic targets in autoimmunity.
Collapse
|
1735
|
Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001; 28:903-5. [PMID: 11781654 DOI: 10.1038/sj.bmt.1703237] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2001] [Accepted: 08/16/2001] [Indexed: 12/29/2022]
Abstract
Evans syndrome is a rare disorder characterized by combined autoimmune thrombocytopenia (ITP) and autoimmune hemolytic anemia (AIHA). Standard treatments consist of transfusions, corticosteroids, splenectomy, IVIG, anabolic steroids, vincristine, alkylating agents, or cyclosporine. In a patient with refractory disease, an allogeneic hematopoietic stem cell transplant (HSCT) resulted in complete clinical and serologic remission for more than 30 months. Allogeneic HSCT may be the only current curative therapy for Evans syndrome but may also be complicated by significant toxicities.
Collapse
MESH Headings
- Adrenal Cortex Hormones/therapeutic use
- Adult
- Anemia, Hemolytic, Autoimmune/drug therapy
- Anemia, Hemolytic, Autoimmune/surgery
- Anemia, Hemolytic, Autoimmune/therapy
- Antibodies, Monoclonal/therapeutic use
- Autoimmune Diseases/drug therapy
- Autoimmune Diseases/surgery
- Autoimmune Diseases/therapy
- Combined Modality Therapy
- Danazol/therapeutic use
- Graft vs Host Disease/etiology
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunoglobulins, Intravenous/therapeutic use
- Immunosuppressive Agents/adverse effects
- Immunosuppressive Agents/therapeutic use
- Infliximab
- Male
- Mycophenolic Acid/analogs & derivatives
- Mycophenolic Acid/therapeutic use
- Opportunistic Infections/etiology
- Prednisone/therapeutic use
- Purpura, Thrombotic Thrombocytopenic/etiology
- Remission Induction
- Salvage Therapy
- Splenectomy
- Syndrome
- Thrombocytopenia/drug therapy
- Thrombocytopenia/surgery
- Thrombocytopenia/therapy
- Transplantation Conditioning/adverse effects
- Transplantation, Homologous
- Vincristine/therapeutic use
Collapse
|
1736
|
Abstract
Chronic hepatitis C is associated with, and may trigger or exacerbate, an extraordinary variety of extrahepatic manifestations. Most of these manifestations affect the skin, the most frequent and important of which are the leukocytoclastic vasculitis of MC type II and PCT. The former is an example of an autoimmune disorder triggered by HCV infection, whereas PCT is a skin disease caused by hepatic overproduction of uro- and 7-carboxyl porphyrins caused by increased oxidative stress in hepatocytes. Currently available effective therapies of CHC (IFN, ribavirin) may also trigger or exacerbate extrahepatic manifestations, especially including autoimmune thyroiditis, skin rashes, and hemolytic anemia.
Collapse
|
1737
|
Launay D. [Hematopoietic stem cell transplantation in the treatment of severe autoimmune diseases]. Rev Med Interne 2001; 22:1138. [PMID: 11817133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
1738
|
|
1739
|
Rao S, Vasu C, Martinez O, Kaithamana S, Prabhakar BS, Holterman MJ. Targeted delivery of anti-CTLA-4 antibody downregulates T cell function in vitro and in vivo. Clin Immunol 2001; 101:136-45. [PMID: 11683572 DOI: 10.1006/clim.2001.5119] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
CTLA-4 is a T cell surface molecule that binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells and downregulates T cell function. Therefore, we wanted to test whether antigen-specific activated T cells could be inhibited through directed CTLA-4 signaling using a bispecific antibody (BiAb) capable of simultaneously binding to CTLA-4 and a tissue-specific antigen. The BiAb was prepared by linking two separate monoclonal antibodies against CTLA-4 and the thyroid-stimulating hormone receptor (TSHR). The mouse B cell lymphoma line M12 (H2(d)) was used to induce alloreactive T cells in CBA/J mice (H2(k)); M12 cells stably transfected with the cDNA encoding murine TSHR (mM12) were used to restimulate the alloresponse in vitro. Results of assays for in vitro T cell proliferation, IL-2 production, and cytotoxicity in the presence of BiAb demonstrated that the BiAb could inhibit the T cell alloresponse when stimulated with mM12 cells but not with M12 cells. This effect was dependent on binding of TSHR-bound BiAb to CTLA-4, since the addition of soluble CTLA-4-Ig blocked the inhibitory effect. Injection of mM12 cells, along with the BiAb, not with antibodies against TSHR or CTLA-4 either separately or together, into CBA/J mice (H2(k)) downregulated alloreactive T cell responses. Our study demonstrated that the presence of CTLA-4 signaling molecules on the surface of target cells can protect those cells from immune attack by antigen-specific T cells and suggested that a similar approach could have potential therapeutic value in transplant rejection and tissue-specific autoimmune diseases.
Collapse
|
1740
|
Esfandiari E, McInnes IB, Lindop G, Huang FP, Field M, Komai-Koma M, Wei X, Liew FY. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:5338-47. [PMID: 11673550 DOI: 10.4049/jimmunol.167.9.5338] [Citation(s) in RCA: 95] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Serum from patients with systemic lupus erythematosus (SLE) contained significantly higher concentrations of IL-18 than normal individuals. MRL/lpr mice, which develop spontaneous lupus-like autoimmune disease, also had higher serum levels of IL-18 than wild-type MRL/++ mice. Daily injections of IL-18 or IL-18 plus IL-12 resulted in accelerated proteinuria, glomerulonephritis, vasculitis, and raised levels of proinflammatory cytokines in MRL/lpr mice. IL-18-treated MRL/lpr mice also developed a "butterfly" facial rash resembling clinical SLE. In contrast, MRL/lpr mice treated with IL-18 plus IL-12 did not develop a facial rash. The facial lesion in the IL-18-treated mice showed epidermal thickening with intense chronic inflammation accompanied by increased apoptosis, Ig deposition, and early systemic Th2 response compared with control or IL-12 plus IL-18-treated mice. These data therefore show that IL-18 is an important mediator of lupus-like disease and may thus be a novel target for therapeutic intervention of spontaneous autoimmune diseases.
Collapse
|
1741
|
Wauben MH. Immunological mechanisms involved in experimental peptide immunotherapy of T-cell-mediated diseases. Crit Rev Immunol 2001; 20:451-69. [PMID: 11396681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Current therapies for autoimmune diseases and allergy involve general immune suppression. However, the ideal therapy should specifically eliminate or modulate the (auto)pathogenic immune response or, alternatively, it should reinforce the regulatory response, without affecting the overall function of the immune system. This could be achieved by antigen-specific immunotherapy. Antigen-specific immunotherapy has received ample attention in the last years, and several clinical trials attempting to treat autoimmune diseases or allergy through the induction of antigen-specific tolerance or immune deviation have been conducted, albeit with varying success. Recent advances in our understanding of peripheral tolerance, regulatory T cells, and routes of antigen administration have resulted in better insight into the different working mechanisms and potential target molecules of antigen-specific immunotherapy. The experimental animal models and new technological developments force the pace in the development of these immunotherapies. The current review addresses several aspects of antigen-specific immunotherapies and focuses on the mechanisms of the different approaches in experimental autoimmune and allergy models.
Collapse
|
1742
|
Zhang X, Izikson L, Liu L, Weiner HL. Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:4245-53. [PMID: 11591746 DOI: 10.4049/jimmunol.167.8.4245] [Citation(s) in RCA: 352] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
CD25(+)CD4(+) T cells are naturally occurring regulatory T cells that are anergic and have suppressive properties. Although they can be isolated from the spleens of normal mice, there are limited studies on how they can be activated or expanded in vivo. We found that oral administration of OVA to OVA TCR transgenic mice resulted in a modification of the ratio of CD25(+)CD4(+) to CD25(-)CD4(+) cells with an increase of CD25(+)CD4(+) T cells accompanied by a decrease of CD25(-)CD4(+) T cells. The relative increase in CD25(+)CD4(+) T cells persisted for as long as 4 wk post feeding. We also found that CTLA-4 was dominantly expressed in CD25(+)CD4(+) T cells and there was an increase in the percentage of CD25(+)CD4(+) T cells expressing CTLA-4 in OVA-fed mice. In contrast to CD25(-)CD4(+) cells, CD25(+)CD4(+) cells from fed mice proliferated only minimally to OVA or anti-CD3 and secreted IL-10 and elevated levels of TGF-beta(1) following anti-CD3 stimulation. CD25(+)CD4(+) cells from fed mice suppressed the proliferation of CD25(-)CD4(+) T cells in vitro more potently than CD25(+)CD4(+) T cells isolated from unfed mice, and this suppression was partially reversible by IL-10 soluble receptor or TGF-beta soluble receptor and high concentration of anti-CTLA-4. With anti-CD3 stimulation, CD25(+)CD4(+) cells from unfed mice secreted IFN-gamma, whereas CD25(+)CD4(+) cells from fed mice did not. Adoptive transfer of CD25(+)CD4(+) T cells from fed mice suppressed in vivo delayed-type hypersensitivity responses in BALB/c mice. These results demonstrate an Ag-specific in vivo method to activate CD25(+)CD4(+) regulatory T cells and suggest that they may be involved in oral tolerance.
Collapse
|
1743
|
Yura M, Takahashi I, Terawaki S, Hiroi T, Kweon MN, Yuki Y, Kiyono H. Nasal administration of cholera toxin (CT) suppresses clinical signs of experimental autoimmune encephalomyelitis (EAE). Vaccine 2001; 20:134-9. [PMID: 11567757 DOI: 10.1016/s0264-410x(01)00278-x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Cholera toxin (CT), a major enterotoxin produced by Vibrio cholerae, elicits mucosal adjuvant activities by inducing antigen-specific CD4+ T cells secreting T helper type 2 (Th2) cytokines. Experimental autoimmune encephalomyelitis (EAE) is induced by Th1 cells specific for myelin-derived antigens. We induced EAE in C57BL/6 mice with myelin oligodendrocyte glycoprotein (MOG) 35-55 and CT was nasally administered as an immunomodulator on day 7 following MOG challenge. Clinical severity in the CT-treated mice was milder when compared to PBS-treated mice, while the levels of expression of interleukin (IL)-12 and interferon (IFN)-gamma in the central nervous system (CNS) of CT-treated mice were lower than PBS-treated mice. Thus, nasal administration of the mucosal immunomodulator CT ameliorated the severity of EAE, which was associated with the suppression of Th1 cell responses.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Adjuvants, Immunologic/pharmacology
- Adjuvants, Immunologic/therapeutic use
- Administration, Intranasal
- Amino Acid Sequence
- Animals
- Autoimmune Diseases/immunology
- Autoimmune Diseases/therapy
- Central Nervous System/immunology
- Central Nervous System/metabolism
- Cholera Toxin/administration & dosage
- Cholera Toxin/immunology
- Cholera Toxin/pharmacology
- Cholera Toxin/therapeutic use
- Drug Evaluation, Preclinical
- Encephalomyelitis, Autoimmune, Experimental/immunology
- Encephalomyelitis, Autoimmune, Experimental/therapy
- Female
- Glycoproteins/immunology
- Glycoproteins/toxicity
- Humans
- Interferon-gamma/metabolism
- Interleukin-12/metabolism
- Mice
- Mice, Inbred C57BL
- Myelin-Oligodendrocyte Glycoprotein
- Peptide Fragments/immunology
- Peptide Fragments/toxicity
- Severity of Illness Index
- Spleen/immunology
- Th1 Cells/immunology
- Th2 Cells/immunology
- Th2 Cells/metabolism
Collapse
|
1744
|
|
1745
|
Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med (Berl) 2001; 79:552-65. [PMID: 11692152 DOI: 10.1007/s001090100259] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/21/2001] [Indexed: 11/29/2022]
Abstract
An important subgroup of human cellular receptors uses peptides as signaling molecules. Modifications of these signaling peptides, usually by amino acid substitutions in crucial receptor contact sites (i.e., altered peptide ligands, APLs), is an approach for highly selective and specific modulation of the receptor function. One of the major applications of APLs is immunology, where APLs have been examined for therapeutic modulation of T cell function, both for diseases characterized by unwanted activation of T cells (e.g., autoimmune diseases) and for disorders with suboptimal T cell activation (e.g., immunotherapy of cancers and infectious disorders). APLs also occur in vivo, for example, as escape mutants of infectious agents, and play an important role in thymic positive selection. We summarize current knowledge of the basic mechanisms of the effects of APLs with special focus on T cell receptor signaling and the use of APLs for the treatment of autoimmune diseases.
Collapse
|
1746
|
Rewald E, Francischetti MM, Nydegger UE. IVIG-pools: regulatory gifts--transiting from harmony toward harmonious immunoglobulins: why? and why not? Transfus Apher Sci 2001; 25:113-37. [PMID: 11761275 DOI: 10.1016/s1473-0502(01)00103-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Based on 'initial conditions' which depend on each donors' exposure to a unique environment, a pooled intravenous immunoglobulin (IVIG) product transfers its immunoglobulin molecule repertoire, unchanged, to the altered host. The relay function of the cell-bound receptors, especially that of the inhibitory Fc(gamma)RIIB, may then allow sufficient amplification to make regulatory activity possible. To the clinician, IVIG may be considered a tool to promote reversal of the dysregulation causing autoimmune disease. Generically, IVIG may be seen as a promoter allowing a progression from harm by an inflammatory/fibrotic reaction, then down-regulating toward restitutio ad integrum. By modifying natural processes, IVIG may play minor roles in promoting defense against spontaneous bleeding and, perhaps, stimulating remyelination. The wide spectrum of IVIG specificities, by reflecting evolutionary epitope selection, may not further destabilize cell/molecule disarray in the affected host. Benefit to the patient by IVIG treatment cannot be predicted nor can potentially severe or even fatal accidents entirely be excluded. Important aspects of IVIG treatment still await clarification including dosage, timing and the isotype form. In the foreseeable future it does not seem that biotechnological advances will match the physiologic harmony of IVIG, leaving antibody characteristics aside.
Collapse
|
1747
|
Melo ME, El-Amine M, Tonnetti L, Fleischman L, Scott DW. Gene therapeutic approaches to induction and maintenance of tolerance. Int Rev Immunol 2001; 20:627-45. [PMID: 11890616 DOI: 10.3109/08830180109045582] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Tolerance induction would be an ideal way to treat autoimmune diseases, especially if achievable in primed individuals. Moreover, specific tolerance would preclude the need for immunosuppressive treatment with its side effects. In this review, we will revisit the historical concepts of tolerance, and introduce a novel approach to tolerance via gene therapy. Our model system is based on the tolerogenicity of IgG carriers and B-cell antigen presentation. Results with this model demonstrate that it is simple and effective even in primed recipients, and has proven efficacy in three autoimmune models. We discuss the mechanisms of tolerance with fusion IgG's and analyze how our model of gene therapy approached can be utilized to fit in the future treatment of autoimmune conditions.
Collapse
|
1748
|
|
1749
|
Abstract
Antibody-based therapy, which is the administration of polyclonal, hyperimmune, or monoclonal antibodies, has emerged as an important therapeutic approach in a wide variety of diseases. Polyclonal intravenous immunoglobulin became available in the early 1980s and supplanted intramuscular IgG in the treatment of antibody-deficiency diseases. During the last 2 decades, intravenous immunoglobulin has shown potent immunomodulatory and anti-inflammatory effects in many diseases. Whether these effects are mediated through specific antibody or Fc-receptor interactions is unclear. This review examines some of the current and future prospects for antibody-based therapy.
Collapse
|
1750
|
Legge KL, Bell JJ, Li L, Gregg R, Caprio JC, Zaghouani H. Multi-modal antigen specific therapy for autoimmunity. Int Rev Immunol 2001; 20:593-611. [PMID: 11890614 DOI: 10.3109/08830180109045580] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Peripheral tolerance, represents an attractive strategy to down-regulate previously activated T cells and suppress an ongoing disease. Herein, immunoglobulins (Igs) were used to deliver self and altered self peptides for efficient peptide presentation without costimulation to test for modulation of experimental allergic encephalomyelitis (EAE). Accordingly, the encephalitogenic proteolipid protein (PLP) sequence 139-151 (referred to as PLP1) and an altered form of PLP1 known as PLP-LR were genetically expressed on Igs and the resulting Ig-PLP1 and Ig-PLP-LR were tested for efficient presentation of the peptides and for amelioration of ongoing EAE. Evidence is presented indicating that Ig-PLP1 as well as Ig-PLP-LR given in saline to mice with ongoing clinical EAE suppresses subsequent relapses. However, aggregation of both chimeras allows crosslinking of Fcgamma receptors (FcgammaRs) and induction of IL-10 production by APCs but does not promote the up-regulation of costimulatory molecules. Consequently, IL-10 displays bystander suppression and synergizes with presentation without costimulation to drive effective modulation of EAE. As Ig-PLP1 is more potent than Ig-PLP-LR in the down-regulation of T cells, we conclude that peptide affinity plays a critical role in this multi-modal approach of T cell modulation.
Collapse
|